ArticleBlood research2025
Awareness and real-world practices in chronic lymphocytic leukemia: insights from a nationwide survey of Korean hematologists.
Article in Blood research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe incidence of chronic lymphocytic leukemia (CLL) is rising in Korea; however, clinical management often diverges from international guidelines due to limited clinical experience, restricted access to diagnostics, and delayed reimbursement for novel agents. This study aimed to assess Korean hematologists' awareness, clinical practices, and perceived barriers in the management of CLL.
methodsA nationwide, web-based survey was conducted between May 29 and June 19, 2023, targeting hematologists registered with the Korean Society of Hematology who were actively treating patients with CLL. The 15-item questionnaire addressed clinical experience, treatment approaches, use of bruton tyrosine kinase inhibitor (BTKi), awareness and application of prognostic tools, access to molecular diagnostics, reimbursement priorities, and perceived need for national clinical guidelines. A total of 89 hematologists completed the survey.
resultsPatient caseloads varied, with 41.6% of physicians managing 10-19 patients over the prior six months. Treatment patterns were heterogeneous, and undertreatment was commonly attributed to patient refusal (33.7%) and advanced age (10.1%). Despite reimbursement limitations, 15.7% reported prescribing BTKis in ≥ 40% of their patients, although adverse events and intolerance were frequently cited challenges. Awareness of prognostic indices was high, yet their implementation was inconsistent. Access to essential molecular diagnostics was suboptimal; 53% lacking Immunoglobulin heavy-chain variable region gene (IGHV) mutation testing and 43% lacked measurable residual disease (MRD) assessment, whereas TP53 testing was broadly available. Nearly half of the respondents prioritized second-generation BTKis for first-line reimbursement, and 94.4% endorsed the need for Korean-specific clinical guidelines.
conclusionThis survey highlights gaps between international recommendations and Korean real-world practice, emphasizing the need for improved diagnostic availability, timely reimbursement of targeted agents, and development of Korea-specific clinical guidelines tailored to the Korean context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.